Analytical Data
-
Gene name
IGKV1-5
- Application
-
Alternative Names
IGKV1-5; Immunoglobulin kappa variable 1-5; Ig kappa chain V-I region CAR; Ig kappa chain V-I region EU; Ig kappa chain V-I region HK102; Ig kappa chain V-I region Kue
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01602
-
Expression Region
1-235aa
-
AA Sequence
MEAPAQLLFLLLLWLPDSTGEIVMTQSPATLSVSPGERATLSCRASQSISNNLAWYQQRPGQAPRLLIYGASSRVTGIPGRFSGSGSGTEFTLSISSLQSEDFAVYFCQQYNDWLLYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
-
Molecular Weight
52.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The IGKV1-5 gene, a member of the immunoglobulin kappa light chain variable region gene family, plays a crucial role in the adaptive immune response. It encodes a variable region that is essential for antibody diversity and specificity, enabling the immune system to recognize a vast array of antigens. Research into IGKV1-5 recombinant proteins has gained momentum due to their potential applications in therapeutic and diagnostic settings. These proteins can be utilized for developing monoclonal antibodies, which are vital in treating various diseases, including cancers and autoimmune disorders. Additionally, studying IGKV1-5 can provide insights into the mechanisms of B cell maturation and the overall process of immunoglobulin gene rearrangement, which is pivotal for understanding adaptive immunity. The ability to produce recombinant IGKV1-5 proteins in vitro facilitates extensive investigations into their structural and functional properties, thereby enabling a deeper understanding of how these proteins contribute to immune responses. Furthermore, exploring variations in the IGKV1-5 gene across different populations can shed light on the genetic factors influencing disease susceptibility and vaccine efficacy. Overall, the study of IGKV1-5 recombinant proteins not only enhances our knowledge of immune system function but also holds promise for advancing therapeutic interventions and improving healthcare outcomes.
